Dunhill Financial’s 10x Genomics TXG Stock Holding History

Dunhill Financial’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$63	Hold	1	–	–	﹤0.01%	1478
2026 Q1	$35	Sell	1 -1	-50%	-$20	﹤0.01%	1685
2025 Q4	$27	Buy	+2	New	+$30	﹤0.01%	1850

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dunhill Financial's TXG Position: Q2 2026 in Review

Dunhill Financial held its 10x Genomics (TXG) position steady in Q2 2026 at 1 share worth $63. The position accounts for ﹤0.01% of the portfolio, ranked #1478.

Dunhill Financial first reported a position in TXG in Q4 2025 and has held it in 3 quarters since. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Dunhill Financial held 1 share of 10x Genomics worth $63 as of Q2 2026.
Dunhill Financial left its 10x Genomics share count unchanged in Q2 2026.
10x Genomics made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #1478 holding.
Dunhill Financial first reported a position in 10x Genomics in Q4 2025 and has held it in 3 quarters since.
392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.